Allergan Plc (NYSE: AGN) reiterated to Buy with price target $350 by Deutsche Bank
Deutsche Bank reiterated Allergan Plc (NYSE: AGN) to Buy with price target $350. Previously, Deutsche Bank rated Allergan Plc (NYSE: AGN) to Buy with price
target $336 on 03/03/2015, when the stock price was valued at $294.64. Since then, Allergan Plc's stock price has gained 8% as of 08/07/2015's recent price of $317.01. If you had followed Deutsche Bank's previous recommendation on AGN, you would have gained 8% of your investment in 157 days.
Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company?s operations are based predominantly in the United States and India, with its key commercial market being the United States. In July 2008, Watson and Mylan Inc. announced that Mylan Inc. has acquired Watson?s 50% interest in the Somerset Pharmaceuticals, Inc. joint venture. In December 2009, the Company completed the acquisition of Arrow Group.
is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank
. This division is one of the largest global asset managers.